A Phase II Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme.

Trial Profile

A Phase II Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2012

At a glance

  • Drugs Bevacizumab; Temsirolimus
  • Indications Glioblastoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jun 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 01 Jun 2010 Actual end date (February 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top